doi:10.3969/j.issn.1004-583X.2022.10.012

Abstract

CLC Number:

R749.3

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.10.012

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I10/942

Figures/Tables 1

References 25

[1]	Ding D, Lawson KD, Kolbe-Alexander TL, et al. The economic burden of physical inactivity: A global analysis of major non-communicable diseases[J]. Lancet, 2016, 388(10051):1311-1324. doi: 10.1016/S0140-6736(16)30383-X pmid: 27475266
[2]	Leucht S, Siafis S, Engel RR, et al. How efficacious are antipsychotic drugs for schizophrenia? an interpretation based on 13 effect size indices[J]. Schizophr Bull, 2022, 48(1):27-36. doi: 10.1093/schbul/sbab094 URL
[3]	Semahegn A, Torpey K, Manu A, et al. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis[J]. Syst Rev, 2020, 9(1):17. doi: 10.1186/s13643-020-1274-3 pmid: 31948489
[4]	Deng M, Zhai S, Ouyang X, et al. Factors influencing medication adherence among patients with severe mental disorders from the perspective of mental health professionals[J]. BMC Psychiatry, 2022, 22(1):22. doi: 10.1186/s12888-021-03681-6 pmid: 34996394
[5]	Clifford L, Crabb S, Turnbull D, et al. A qualitative study of medication adherence amongst people with schizophrenia[J]. Arch Psychiatr Nurs, 2020, 34(4):194-199. doi: 10.1016/j.apnu.2020.06.002 URL
[6]	Loots E, Goossens E, Vanwesemael T, et al. Interventions to improve medication adherence in patients with schizophrenia or bipolar disorders: A systematic review and meta-analysis[J]. Int J Environ Res Public Health, 2021, 18(19):10213. doi: 10.3390/ijerph181910213 URL
[7]	Xu DR, Gong W, Gloyd S, et al. Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China[J]. Schizophr Res, 2018, 201:307-314. doi: S0920-9964(18)30271-8 pmid: 29807806
[8]	Sajatovic M, Velligan DI, Weiden PJ, et al. Measurement of psychiatric treatment adherence[J]. J Psychosom Res, 2010, 69(6):591-599. doi: 10.1016/j.jpsychores.2009.05.007 pmid: 21109048
[9]	Xu DR, Xiao S, He H, et al. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial[J]. PLoS Med, 2019, 16(4):e1002785. doi: 10.1371/journal.pmed.1002785 URL
[10]	McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects[J]. J Clin Epidemiol, 2014, 67(3):267-277. doi: 10.1016/j.jclinepi.2013.08.015 pmid: 24275499
[11]	Mehas N, Hudmon KS, Jaynes H, et al. Impact of electronic medication reminder caps on patient adherence and blood pressure[J]. J Pharm Technol, 2021, 37(5):234-243.
[12]	Yaegashi H, Kirino S, Remington G, et al. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis[J]. CNS Drugs, 2020, 34(6):579-598. doi: 10.1007/s40263-020-00713-9 pmid: 32219681
[13]	Baumgartner PC, Vrijens B, Allemann S, et al. Delta T, a useful indicator for pharmacy dispensing data to monitor medication adherence[J]. Pharmaceutics, 2022, 14(1):103. doi: 10.3390/pharmaceutics14010103 URL
[14]	Yalcin-Siedentopf N, Wartelsteiner F, Kaufmann A, et al. Measuring adherence to medication in schizophrenia: The relationship between attitudes toward drug therapy and plasma levels of new-generation antipsychotics[J]. Int J Neuropsychopharmacol, 2014, 18(5):pyu091. doi: 10.1093/ijnp/pyu091 URL
[15]	Smith RL, Tveito M, Kyllesø L, et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs-A study based on blood sample analyses from 24, 239 patients[J]. Eur Neuropsychopharmacol, 2020, 37:64-69. doi: 10.1016/j.euroneuro.2020.06.007 URL
[16]	Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017[J]. Pharmacopsychiatry, 2018, 51(1-02):e1. doi: 10.1055/s-0037-1600991 pmid: 29390205
[17]	Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence[J]. Med Care, 1986, 24(1):67-74. pmid: 3945130
[18]	Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses[J]. Schizophr Res, 2000, 42(3):241-247. pmid: 10785582
[19]	Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity[J]. Psychol Med, 1983, 13(1):17. doi: 10.1017/S0033291700050029 URL
[20]	Byerly MJ, Nakonezny PA, Rush AJ. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder[J]. Schizophr Res, 2008, 100(1-3):60-69. doi: 10.1016/j.schres.2007.12.470 pmid: 18255269
[21]	Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia[J]. Schizophr Bull, 1994, 20(2):297-310. pmid: 7916162
[22]	Brain C, Sameby B, Allerby K, Twelve months of electronic monitoring (MEMS^®) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophreni[J]. Eur Neuropsychopharmacol, 2014, 24(2):215-222. doi: 10.1016/j.euroneuro.2013.11.013 URL
[23]	Lam WY, Fresco P. Medication adherence measures: An overview[J]. Biomed Res Int, 2015, 2015:217047.
[24]	Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications[J]. Psychiatr Serv, 2007, 58(9):1187-1192. doi: 10.1176/ps.2007.58.9.1187 URL
[25]	Kwan YH, Weng SD, Loh DHF, et al. Measurement properties of existing patient-reported outcome measures on medication adherence: Systematic review[J]. J Med Internet Res, 2020, 22(10):e19179. doi: 10.2196/19179 URL

组别	优点	缺点
客观评估方式^[23]
药片计数^[8,22]	最准确的方式	①适合日常使用; ②不能监测患者的实际摄入量^[11]
电子监测技术^[11,22]	①准确记录开盖情况; ②规避了数药片计数过于繁琐和血药浓度监测方法存在个体间差异的局; ③提高患者对治疗的依从性	①昂贵,不适合大规模开展; ②对老年人来说使用困难; ③不能监测患者的实际摄入量^[11]
电子药房^[13]	用于大群体的研究	不能确认患者是否真实服药^[11]
监测血药浓度^[14]	最客观的方式	①受个体差异影响大; ②是一种侵入性的,昂贵的方式;
主观评估方法^[24]
自评量表他评量表	简单易用、无创、便宜、在大型研究的临床环境中最有用^[25]	①没有证据表明该药物被摄入; ②不准确,容易被患者歪曲; ③效度差

组别	优点	缺点
客观评估方式^[23]
药片计数^[8,22]	最准确的方式	①适合日常使用; ②不能监测患者的实际摄入量^[11]
电子监测技术^[11,22]	①准确记录开盖情况; ②规避了数药片计数过于繁琐和血药浓度监测方法存在个体间差异的局; ③提高患者对治疗的依从性	①昂贵,不适合大规模开展; ②对老年人来说使用困难; ③不能监测患者的实际摄入量^[11]
电子药房^[13]	用于大群体的研究	不能确认患者是否真实服药^[11]
监测血药浓度^[14]	最客观的方式	①受个体差异影响大; ②是一种侵入性的,昂贵的方式;
主观评估方法^[24]
自评量表他评量表	简单易用、无创、便宜、在大型研究的临床环境中最有用^[25]	①没有证据表明该药物被摄入; ②不准确,容易被患者歪曲; ③效度差

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 25

Related Articles 12

Recommended Articles

Metrics

Comments

[1]	Lin Xiaodong, Qu Junmin, Yu Jun, Li Jinming. Risk of violence in schizophrenia patients with obsessive-compulsive thinking versus behaviors: A comparative study [J]. Clinical Focus, 2023, 38(3): 255-259.
[2]	Feng Xinmei. Effect of olanzapine on symptoms, safety scores and related serum factors of schizophrenia in patients [J]. Clinical Focus, 2021, 36(12): 1114-1117.
[3]	Sun Yajun;Gao Qin;Zhang Jingjing;Chen Jinshan. Effect of different periodical modified electroconvulsive therapy on cognitive functions of patients with schizophrenia [J]. Clinical Focus, 2015, 30(1): 82-85.
[4]	. [J]. Clinical Focus, 2011, 26(23): 2104-0.
[5]	. [J]. CLINICAL FOCUS, 2011, 26(14): 1247-1248.
[6]	. [J]. CLINICAL FOCUS, 2010, 25(19): 1717-1718.
[7]	. [J]. CLINICAL FOCUS, 2010, 25(3): 269-271.
[8]	. [J]. CLINICAL FOCUS, 2008, 23(13): 961-962.
[9]	. [J]. CLINICAL FOCUS, 2006, 21(17): 1252-1253.
[10]	. [J]. CLINICAL FOCUS, 2006, 21(15): 1085-1085.
[11]	. [J]. CLINICAL FOCUS, 2006, 21(6): 432-432.
[12]	. [J]. CLINICAL FOCUS, 2004, 19(22): 1279-1279.